Glizora™-80 M 500 Tablets

10X10 Tablets

Glizora™-80 M 500 Tablets combine the dual action of Gliclazide, a sulfonylurea, and Metformin, a biguanide, to provide effective glycemic control in patients with Type 2 Diabetes Mellitus (T2DM). This fixed-dose combination improves insulin secretion, reduces hepatic glucose production, and enhances peripheral insulin sensitivity.

It is designed for patients who require better blood sugar control when monotherapy with either Gliclazide or Metformin alone is insufficient.

• Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal discomfort).

• Hypoglycemia (dizziness, sweating, confusion, hunger).

• Lactic acidosis (rare but serious; linked with metformin).

• Weight gain (possible with Gliclazide).

• Headache, fatigue, taste disturbances.

• To be used as an adjunct to diet and exercise in adults with Type 2 Diabetes Mellitus.

• Intended for patients inadequately controlled with metformin alone or gliclazide alone.

• Risk of hypoglycemia is higher when used with other antidiabetic drugs or alcohol.

• Prolonged use may require renal and hepatic function monitoring.

• Elderly patients need dose adjustment due to decreased renal function.

Do not use Glizora™-80 M 500 in patients with:

• Type 1 Diabetes Mellitus.

• Diabetic ketoacidosis (with or without coma).

• Severe renal impairment (eGFR < 30 ml/min/1.73m²).

• Severe hepatic dysfunction.

• History of lactic acidosis.

• Hypersensitivity to Gliclazide, Metformin, or any excipients.

• Pregnancy and breastfeeding (unless prescribed by doctor).

• Avoid alcohol consumption (may increase risk of hypoglycemia and lactic acidosis).

• Stop medication temporarily before contrast radiology procedures or major surgery.

• Regular monitoring of blood glucose, HbA1c, kidney function, and liver enzymes is recommended.

• Use with caution in elderly patients.

• As directed by physician.

• Typical adult dose: One tablet once or twice daily, preferably with meals to reduce GI side effects.

• Dose must be individualized based on glycemic response and tolerance.

• Increased hypoglycemia risk with: Insulin, other sulfonylureas, beta-blockers, NSAIDs, fluoroquinolones.

• Decreased effect with: Corticosteroids, oral contraceptives, diuretics, thyroid hormones.

• Avoid alcohol – may potentiate lactic acidosis and hypoglycemia.

• Take exactly as prescribed by your healthcare provider.

• Do not skip meals while on this medication.

• Avoid excessive alcohol intake.

• Maintain healthy lifestyle with balanced diet and regular exercise.

• Regularly monitor blood sugar and report unusual symptoms.

• Do not discontinue without consulting your doctor.

• Storage: Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

• International Diabetes Federation (IDF) Guidelines, 2023.

• American Diabetes Association (ADA) Standards of Medical Care in Diabetes, 2024.

• European Association for the Study of Diabetes (EASD) consensus on T2DM management.

• Drug information databases: PubMed, Medscape, Drugs.com.